Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Authors: Michael D. Shapiro, Joshua Miles, Hagai Tavori, Sergio Fazio
Journal: Annals of Internal Medicine (2017)

Letters6 March 2018Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorMichael D. Shapiro, DO, Joshua Miles, BS, Hagai Tavori, PhD, and Sergio Fazio, MD, PhDMichael D. Shapiro, DOOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this author, Joshua Miles, BSOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this author, Hagai Tavori, PhDOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this author, and Sergio Fazio, MD, PhDOregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-2485 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) revolutionized the understanding of lipoprotein metabolism (1). Rapid translation of genetic insights led to the development of a new class of therapeutic agents that antagonize plasma PCSK9 and cause remarkable reductions (between 45% and 75%) in low-density lipoprotein (LDL) cholesterol levels. A large randomized controlled trial recently showed that adding a PCSK9 inhibitor in patients with established vascular disease who were already treated with optimized statin therapy caused statistically significant reductions in rates of myocardial infarction and stroke (2). Most patients receiving a PCSK9 inhibitor respond with marked reductions in ...References1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6. [PMID: 12730697] CrossrefMedlineGoogle Scholar2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22. [PMID: 28304224] doi:10.1056/NEJMoa1615664 CrossrefMedlineGoogle Scholar3. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63:1278-88. [PMID: 24509273] doi:10.1016/j.jacc.2014.01.006 CrossrefMedlineGoogle Scholar4. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127:2403-13. [PMID: 23690465] doi:10.1161/CIRCULATIONAHA.113.001592 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Oregon Health & Science University, Portland, Oregon (M.D.S., J.M., H.T., S.F.)Acknowledgment: The authors thank Paul Ziajka, MD, for contributing plasma samples for 1 of the participants.Grant Support: Partially supported by National Institutes of Health (National Heart, Lung, and Blood Institute) R01 grant HL-132985 (Dr. Fazio).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2485.Reproducible Research Statement:Study protocol and statistical code: Not available. Data set: Available from Dr. Shapiro (e-mail, [email protected]edu).This article was published at Annals.org on 28 November 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGenetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative ReviewMechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibitionRecent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia TreatmentPCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient SelectionPCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy EraPharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal LipotoxicityThe promising novel therapies for familial hypercholesterolemiaThe Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic DiseasesThe Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular DiseasePCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohortInclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemiaHepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory AntibodiesEfficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experienceProprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL PathwaysInhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-ArtHeparin‐induced lipoprotein precipitation apheresis in dyslipidemic patients: A multiparametric assessmentThe PCSK9 revolution: Current status, controversies, and future directionsUnusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocolUse of PCSK9 Inhibitors in Solid Organ Transplantation RecipientsSmall Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in miceRelationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg dosesFuture role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiologyKeep recycling going: New approaches to reduce LDL-CChanges in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agentsCase reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponseThe Evolving Future of PCSK9 InhibitorsPCSK9Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab TrialsNon-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels 6 March 2018Volume 168, Issue 5Page: 376-379KeywordsBlood plasmaCholesterolDisclosureFamilial hypercholesterolemiaLow density lipoproteinMonoclonal antibodiesMutationMyocardial infarctionStatinsTreatment guidelines ePublished: 28 November 2017 Issue Published: 6 March 2018 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...